annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 49D Peripheral non-small cell lung cancer treated in stereotactic conditions: A
prospective medico-economic French study. (Abstract #TPS289)
L. Claude, B. Prevost, P. Boisselier, F. Gassa, C. Carrie, S. Dussart
Lung Cancer—Metastatic
Brd. 49E Randomized, open-label study of pemetrexed/carboplatin followed by
maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab
followed by maintenance bevacizumab in patients with advanced non-small
cell lung cancer (NSCLC) of nonsquamous histology. (Abstract #TPS290)
R. Zinner, S. Saxman, G. Peng, W. F. Ortuzar
Brd. 49F Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in
patients at risk of bleeding from VEGF-directed therapies. (Abstract
#TPS291)
E. M. Bertino, G. A. Otterson, M. A. Villalona-Calero, S. P. Nana-Sinkam, A. M.
Ghany, K. R. Donthireddy, N. F. Abdel Karim, S. Cantrell, G. S. Phillips
Brd. 49G Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients
with metastatic non-small cell lung cancer (NSCLC) who have Kras or
EGFR-activated tumors. (Abstract #TPS292)
E. T. Lam, G. A. Otterson, K. R. Donthireddy, J. Thurmond, E. Hade, M. C. Coffey,
M. A. Villalona-Calero
Brd. 49H Thymidylate synthetase (TS) immunohistochemistry (IHC): Feasibility in a
routine clinical setting for patients receiving treatment with pemetrexed for
advanced nonsquamous NSCLC. (Abstract #TPS293)
K. M. Kerr, D. A. Fennell, R. N. Shah, M. Kumar, G. Skailes, V. A. Potter, S. Moore,
P. Maxwell, M. Das, M. Nicolson
Brd. 50A Phase II trial evaluating addition of fulvestrant to erlotinib in patients with
stage IIIb/IV non-small cell lung cancer (NSCLC) who are stable on erlotinib
and exhibit immunohistochemical (IHC) or PCR positivity for estrogen or
progesterone receptor (PR). (Abstract #TPS294)
L. Bazhenova, R. Quintana, R. H. Hastings, K. Messer
Brd. 50B Randomized phase II study of erlotinib (E) alone or combined with fulvestrant
(F) in previously treated patients with advanced non-small cell lung cancer
(NSCLC). (Abstract #TPS295)
E. B. Garon, S. M. Dubinett, W. Hosmer, K. L. Reckamp, F. F. Kabbinavar, L.
Goodglick, D. C. Marquez-Garban, L. P. Stabile, J. Siegfried, R. J. Pietras
Brd. 50C Randomized phase II study of human anti-platelet-derived growth factor
receptor alpha (PDGFR�) monoclonal antibody (IMC-3G3) with
paclitaxel/carboplatin (P/C) or P/C alone in first-line treatment of stage IIIb/IV
non-small cell lung cancer (NSCLC). (Abstract #TPS296)
D. E. Gerber, R. A. Brekken, T. Hoang, H. Youssoufian, E. K. Rowinsky, N. Loizos,
G. D. Shah
Lymphoma and Plasma Cell Disorders
Brd. 50D A phase I study of escalating doses of lenalidomide combined with R-CHOP
(R2-CHOP) for front-line treatment of B-cell lymphomas. (Abstract #TPS297)
H. Tilly, F. Morschhauser, G. A. Salles, O. Casasnovas, P. Feugier, T. J. Molina, C.
Haioun, B. Coiffier, Groupe d’Etudes des Lymphomes de l’Adulte (GELA)
Brd. 50E ENGAGE-501: Phase II study investigating the role of epigenetic therapy with
entinostat (SNDX-275) in relapsed and refractory Hodgkin’s lymphoma (HL).
(Abstract #TPS298)
A. Younes, P. J. Rosen, F. J. Hernandez-Ilizaliturri, G. Bociek, Y. L. Kasamon, A.
Copeland, G. T. Lee
Brd. 50F An open-label, single-arm phase II study of everolimus (RAD001) in patients
with relapsed/refractory classical Hodgkin lymphoma (HL). (Abstract
#TPS299)
P. B. Johnston, L. T. Lewis, J. W. Rogerio
330